Interview with Dr. Jay Andersen, Medical Oncologist at Compass Oncology

KUIK Family Focus 101 hosted by Diane Dennis
Dr. Jay Andersen discusses the benefits of the Oncotype DX assay test in women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.  The test provides a more personalized evaluation of recurrence risk, identifying those patients who warrant inclusion of chemotherapy in addition to anti-hormone therapy as part of their treatment plan.

To listen to the interview, click here.